$HUMA 🚨 HUMA Price Alert - Up 2.98% - Cause:
- Q4 2025 Earnings Release (March 2026): Humacyte reported sequential sales drop for Symvess from 703k in Q3 to 439k in Q4, with only 25 units sold, triggering an 8.9 million inventory write-down due to lack of consistent sales history.
- Analyst Downgrade (March 30, 2026): TD Cowen lowered price target on Humacyte from 3.5 to 1.
- Investor Activism Update (March 30, 2026): Continued calls for immediate action plan including closure of non-core programs, production ramp-down, management downsizing, and focus on trauma-only operations to avoid bankruptcy and potential reverse split.
No other material corporate events, partnerships, listings, or non-price-related developments were identified in the monitored period. The rapid price movement appears driven by market dynamics rather than new fundamental catalysts.
